drugset / Trial / NCT02180269

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

NCT02180269

Phase 1 Completed 24 enrolled Janssen Pharmaceutical K.K.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK, study of the way a drug enters and leaves the blood and tissues over time) of single-ascending oral doses of JNJ-54861911 in healthy Japanese male participants.

Timeline

Start
2014-06
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atabecestat Small molecule 25 mg Oral
Subject Atabecestat Small molecule 50 mg Oral
Subject Atabecestat Small molecule 100 mg Oral

Indications

No indication recorded.